On April 5, 2022 Cytonus Therapeutics Inc. (Cytonus), a biotechnology company developing therapeutic products for targeted delivery in vivo, reported that their CSO, Dr. Richard Klemke Ph.D., will present the preclinical progress made on Cytonus’ lead Cargocyte product candidates at the annual AACR (Free AACR Whitepaper) meeting in New Orleans (Press release, Cytonus Therapeutics, APR 5, 2022, View Source [SID1234611476]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Cargocytes loaded with an Oncolytic Virus (CA-OV-VSV) are engineered to actively home, migrate, and penetrate into tumor micrometastatic foci, hours after intravenous administration.
Dr. Klemke will share data demonstrating striking infiltration of engineered Cargocytes into solid tumors in in vivo models of metastatic Triple Negative Breast Cancer (TNBC), localizing and shielding the company’s proprietary Oncolytic Virus construct from immune neutralization and clearance.
Abstract #378: Bioengineering enucleated cell vehicles for tumor targeted intravenous delivery of oncolytic viruses
Session: Nanoparticles and Other Novel Strategies for Drug Delivery, on 4/10/2022.
Session Start Time:
1:30:00 PM
Session End Time:
5:00:00 PM
Location:
Poster Section 24, Poster Board #14
These results highlight the capabilities of Cytonus’ innovative Cargocyte platform in addressing solid tumor penetration challenges. Importantly, Cargocytes offer localized delivery of potent immunotherapies in a controlled manner to enhance their safety profile.
"Oncolytic Viruses are an exciting new option for fighting cancers. However, the immune system is very good at identifying and rapidly neutralizing viruses administered intravenously which greatly limits their anti-cancer efficacy," said Dr. Remo Moomiaie-Qajar, M.D. co-founder and CEO of Cytonus Therapeutics. "Our Cargocyte platform can shield oncolytic viruses from an immune attack and deliver the virus deep into the tumor microenvironment within hours after systemic administration."
"The majority of current therapeutic approaches utilizing oncolytic viruses are relegated to direct intra-tumoral administration. However, cancer is a systemic disease and can spread to multiple sites in the body. Solutions that address the systemic spread of cancer are sorely needed," said Dr. Moomiaie-Qajar, M.D. "Cargocytes are specifically engineered for systemic administration and can deliver viruses to multiple cancer locations in a precise and eloquent way without over burdening the body with large amounts of free virus."
"Our unique approach has been recognized as a vertical move in science from numerous granting organizations including the NIH and California Institute of Regenerative Medicine (CIRM). We are looking to bring our lead candidate CA-OV-VSV to the clinic within a year."
About Cargocyte
Cargocyte products are derived from enucleated cell lines and are uniquely engineered with specific disease targeting molecules to safely transport therapeutic payloads intravenously and deep into difficult-to-reach target tissues. Cargocytes can deliver and actively produce the therapeutic agent of choice on-site in a controlled, predictable, and safe manner. The proprietary Cargocyte technology is a first-in-class therapeutic platform with numerous potential medical applications across unmet therapeutic areas. Cytonus is developing a broad and deep pipeline of bioengineered Cargocytes for targeted delivery of a wide range of therapeutic modalities including Protein, Peptides, RNAs, ASOs, small molecule drugs, viruses, and gene editing agents.